NEW YORK, July 30, 2021 /PRNewswire/ -- DLA Piper
represented Cowen and Company, LLC, Stifel, Nicolaus & Company,
Incorporated and William Blair &
Company, L.L.C., as underwriters in the initial US public offering
of 13,500,000 shares of common stock of MaxCyte, Inc. (Nasdaq:
MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering
platform technologies, at an initial offering price of US$13.00 per share.
MaxCyte has granted the underwriters a 30-day option to purchase
up to 2,025,000 additional shares of common stock at the initial
offering price per share of common stock, less underwriting
discounts and commissions.
The gross proceeds of the offering, before deducting
underwriting discounts and commissions and offering expenses
payable by MaxCyte, are expected to be approximately US$175.5 million, excluding any exercise of the
underwriters' option to purchase additional shares. The offering is
expected to close on or about August 3,
2021, subject to the satisfaction of customary closing
conditions.
"We were pleased to bring together our extensive capital markets
capabilities both in the US and the UK, as well as a deep
understanding of the life sciences sector, to facilitate this IPO,"
said Michael D. Maline, the DLA
Piper partner who led the deal team.
In addition to Maline (New
York), the DLA Piper deal team representing the underwriters
included partners Patrick
O'Malley (San Diego),
Martin Penn (London), Rebecca
McKnight (Austin),
William Bartow (Philadelphia) and Christine Lehr (Raleigh), and associates Kathryn Fortin (San Diego) and Zamzama
Azizi (San Diego).
DLA Piper's global capital markets team represents issuers and
underwriters in registered and unregistered equity, equity-linked
and debt capital markets transactions, including initial public
offerings, follow-on equity offerings, equity-linked securities
offerings, and offerings of investments grade and high-yield debt
securities.
DLA Piper advises on all aspects of the life sciences sector,
combining subject matter experience with considerable knowledge of
the scientific, medical, regulatory, commercial and enforcement
environments facing biopharmaceutical, medical device, research and
diagnostics clients. Recognizing that clients' needs vary, the firm
rapidly organizes and customizes client service teams, whether for
a large pharmaceutical company, a mid-sized medical device client
or a development-stage biotech company.
About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40
countries throughout the Americas, Europe, the Middle
East, Africa and
Asia Pacific, positioning us to
help clients with their legal needs around the world. In certain
jurisdictions, this information may be considered attorney
advertising. dlapiper.com
View original
content:https://www.prnewswire.com/news-releases/dla-piper-advises-underwriters-of-maxcytes-upsized-us-ipo-301345243.html
SOURCE DLA Piper